Financial Ratios Aptose Biosciences Inc. OTC Markets

Stocks

APTO

CA03835T4081

Pharmaceuticals

Market Closed - OTC Markets 18:53:32 02/07/2026 +03			5-day change	1st Jan Change
1.690 ^USD	+0.90%		-.--%	+14.19%

07-02	Hanmi Pharmaceutical Closes Acquisition of Aptose Biosciences	MT
06-30	Hanmi Pharm. Co., Ltd. completed the acquisition of remaining 80.07% stake in Aptose Biosciences Inc..	CI

8e6882d793a6b0a46faea1dcb7.efc3jo_BXRE1Iq78GqYv3p1IMck98oXu6KUKEnjdsms.NbQF1OmpHEAHQZmwL9xHm9MAA6VInNSqt5dlSjCu_QcwxUfe9YBre1ESmg

Published financial data: APTOSE BIOSCIENCES INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Selling General & Admin Expenses, Total	19.46M	14.51M	15.59M	11.15M	13.38M
R&D Expenses	45.98M	28.09M	36.76M	15.1M	11.34M
Other Operating Expenses, Total	65.45M	42.6M	52.36M	26.26M	24.72M
Operating Income	-65.45M	-42.6M	-52.36M	-26.26M	-24.72M
Interest Expense, Total	-	-	-	-207K	-843K
Interest And Investment Income	94K	788K	1.15M	357K	105K
Net Interest Expenses	94K	788K	1.15M	150K	-738K
Currency Exchange Gains (Loss)	-1K	-9K	-2K	-9K	-7K
Other Non Operating Income (Expenses)	-	-	-	686K	-
EBT, Excl. Unusual Items	-65.35M	-41.82M	-51.21M	-25.43M	-25.47M
Other Unusual Items	-	-	-	-	-
EBT, Incl. Unusual Items	-65.35M	-41.82M	-51.21M	-25.43M	-25.47M
Earnings From Continuing Operations	-65.35M	-41.82M	-51.21M	-25.43M	-25.47M
Net Income to Company	-65.35M	-41.82M	-51.21M	-25.43M	-25.47M
Net Income - (IS)	-65.35M	-41.82M	-51.21M	-25.43M	-25.47M
Net Income to Common Incl Extra Items	-65.35M	-41.82M	-51.21M	-25.43M	-25.47M
Net Income to Common Excl. Extra Items	-65.35M	-41.82M	-51.21M	-25.43M	-25.47M
Per Share Items
Net EPS - Basic	-330.12	-203.98	-227.42	-36.38	-10.41
Basic EPS - Continuing Operations	-330.12	-203.98	-227.42	-36.38	-10.41
Basic Weighted Average Shares Outstanding	198K	205K	225K	699K	2.45M
Net EPS - Diluted	-330.12	-203.98	-227.42	-36.38	-10.41
Diluted EPS - Continuing Operations	-330.12	-203.98	-227.42	-36.38	-10.41
Diluted Weighted Average Shares Outstanding	198K	205K	225K	699K	2.45M
Normalized Basic EPS	-206.33	-127.49	-142.14	-22.74	-6.5
Normalized Diluted EPS	-206.33	-127.49	-142.14	-22.74	-6.5
Supplemental Items
EBITDA	-65.3M	-42.48M	-52.27M	-26.22M	-24.7M
EBITA	-65.45M	-42.6M	-52.36M	-26.26M	-24.72M
EBIT	-65.45M	-42.6M	-52.36M	-26.26M	-24.72M
EBITDAR	-64.78M	-42.04M	-51.8M	-25.79M	-24.27M
Normalized Net Income	-40.85M	-26.14M	-32M	-15.89M	-15.92M
Interest on Long-Term Debt	43K	-	-	207K	843K
Supplemental Operating Expense Items
General and Administrative Expenses	19.46M	14.51M	15.59M	11.15M	13.38M
Research And Development Expense From Footnotes	45.98M	28.09M	36.76M	15.1M	11.34M
Net Rental Expense, Total	515K	443K	471K	438K	429K
Imputed Operating Lease Interest Expense	-	-	-	124K	153K
Imputed Operating Lease Depreciation	-	-	-	314K	276K
Stock-Based Comp., R&D Exp. (Total)	3.79M	2.22M	1.37M	346K	198K
Stock-Based Comp., G&A Exp. (Total)	9.16M	2.99M	2.28M	714K	279K
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	12.95M	5.21M	3.65M	1.06M	477K

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Assets
Cash And Equivalents	39.11M	36.97M	9.25M	6.15M	935K
Short Term Investments	40.01M	9.99M	-	-	-
Total Cash And Short Term Investments	79.13M	46.96M	9.25M	6.15M	935K
Prepaid Expenses	2.48M	2.3M	2.04M	2.25M	2.21M
Restricted Cash	-	-	-	555K	3.16M
Other Current Assets, Total	133K	257K	600K	570K	141K
Total Current Assets	81.74M	49.52M	11.89M	9.53M	6.45M
Gross Property Plant And Equipment	2.75M	3.82M	3.7M	3.45M	3.42M
Accumulated Depreciation	-1.96M	-2.31M	-2.61M	-2.85M	-3.24M
Net Property Plant And Equipment	788K	1.51M	1.1M	597K	179K
Other Intangibles, Total	0	0	0	0	0
Other Long-Term Assets, Total	-	-	-	-	3.39M
Total Assets	82.52M	51.03M	12.99M	10.13M	10.01M
Liabilities
Accounts Payable, Total	1.7M	6.33M	6.05M	1.26M	2.91M
Accrued Expenses, Total	6.02M	5.66M	8.83M	2.77M	6.2M
Current Portion of Leases	459K	301K	394K	428K	193K
Total Current Liabilities	8.17M	12.28M	15.27M	4.46M	9.31M
Long-Term Debt	-	-	-	10.02M	27.02M
Long-Term Leases	115K	1M	621K	193K	-
Other Non Current Liabilities	-	-	-	-	855K
Total Liabilities	8.29M	13.29M	15.89M	14.67M	37.18M
Common Stock, Total	437M	438M	445M	457M	460M
Additional Paid In Capital	63.67M	68.87M	72.15M	83.34M	83.81M
Retained Earnings	-423M	-464M	-516M	-541M	-566M
Comprehensive Income and Other	-4.32M	-4.32M	-4.32M	-4.32M	-4.32M
Total Common Equity	74.24M	37.74M	-2.9M	-4.54M	-27.17M
Total Equity	74.24M	37.74M	-2.9M	-4.54M	-27.17M
Total Liabilities And Equity	82.52M	51.03M	12.99M	10.13M	10.01M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	205K	207K	524K	2.55M	2.55M
ECS Total Common Shares Outstanding	205K	205K	265K	2.01M	2.55M
Book Value / Share	362.26	183.87	-10.96	-2.26	-10.64
Tangible Book Value	74.24M	37.74M	-2.9M	-4.54M	-27.17M
Tangible Book Value Per Share	362.26	183.87	-10.96	-2.26	-10.64
Total Debt	574K	1.3M	1.02M	10.64M	27.21M
Net Debt	-78.55M	-45.66M	-8.24M	4.49M	26.28M
Debt Equivalent Oper. Leases	4.12M	3.54M	3.77M	3.5M	3.43M
Account Code - Inventory Valuation	-	-	-	3	3
Machinery, Total	707K	535K	366K	151K	123K
Full Time Employees	41	35	35	13	14
Part Time Employees	1	1	1	-	-

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Net Income	-65.35M	-41.82M	-51.21M	-25.43M	-25.47M
Depreciation & Amortization - CF	622K	528K	466K	404K	22K
Depreciation & Amortization, Total	622K	528K	466K	404K	22K
(Gain) Loss From Sale Of Asset	-	16K	-	76K	-
Stock-Based Compensation (CF)	12.95M	5.21M	3.65M	1.06M	477K
Other Operating Activities, Total	7.52M	-21K	93K	-604K	1.27M
Change In Accounts Payable	-472K	4.63M	-280K	-4.79M	1.65M
Change in Other Net Operating Assets	1.43M	-856K	2.68M	-6.7M	53K
Cash from Operations	-43.3M	-32.32M	-44.59M	-35.98M	-21.99M
Capital Expenditure	-212K	-24K	-29K	-5K	-
Sale of Property, Plant, and Equipment	-	-	-	23K	-
Investment in Marketable and Equity Securities, Total	-35M	30.09M	9.99M	-	-
Other Investing Activities, Total	-	-	-	-	-
Cash from Investing	-35.21M	30.07M	9.96M	18K	-
Long-Term Debt Issued, Total	-	-	-	10M	18.65M
Total Debt Issued	-	-	-	10M	18.65M
Long-Term Debt Repaid, Total	-	-	-	-	-100K
Total Debt Repaid	-	-	-	-	-100K
Issuance of Common Stock	226K	116K	6.91M	23.44M	829K
Other Financing Activities, Total	-	-	-	-21K	-
Cash from Financing	226K	116K	6.91M	33.41M	19.38M
Foreign Exchange Rate Adjustments	7K	-4K	2K	-	-
Net Change in Cash	-78.28M	-2.14M	-27.72M	-2.54M	-2.61M
Supplemental Items
Levered Free Cash Flow	-26.03M	-16.6M	-25.82M	-26.66M	-12.53M
Unlevered Free Cash Flow	-26.03M	-16.6M	-25.82M	-26.53M	-12M
Change In Net Working Capital	-1.52M	-4.32M	-2.81M	11.58M	-2.95M
Net Debt Issued / Repaid	-	-	-	10M	18.55M

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Profitability
Return on Assets	-39.18	-39.87	-102.23	-141.98	-153.45
Return on Total Capital	-42	-46.77	-176.13	-779.6	-504.8
Return On Equity %	-67.67	-74.7	-293.96	683.23	160.63
Return on Common Equity	-67.67	-74.7	-293.96	683.23	160.63
Short Term Liquidity
Current Ratio	10	4.03	0.78	2.14	0.69
Quick Ratio	9.68	3.82	0.61	1.38	0.1
Operating Cash Flow to Current Liabilities	-5.3	-2.63	-2.92	-8.07	-2.36
Long Term Solvency
Total Debt/Equity	0.77	3.45	-34.99	-234.18	-100.16
Total Debt / Total Capital	0.77	3.34	-53.82	174.52	61.84K
LT Debt/Equity	0.15	2.65	-21.41	-224.76	-99.45
Long-Term Debt / Total Capital	0.15	2.57	-32.93	167.5	61.4K
Total Liabilities / Total Assets	10.04	26.04	122.33	144.86	371.34
EBIT / Interest Expense	-	-	-	-126.85	-29.33
EBITDA / Interest Expense	-	-	-	-124.57	-28.79
(EBITDA - Capex) / Interest Expense	-	-	-	-124.6	-28.79
Total Debt / EBITDA	-0.01	-0.03	-0.02	-0.41	-1.12
Net Debt / EBITDA	1.21	1.09	0.16	-0.17	-1.08
Total Debt / (EBITDA - Capex)	-0.01	-0.03	-0.02	-0.41	-1.12
Net Debt / (EBITDA - Capex)	1.21	1.09	0.16	-0.17	-1.08
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	17.41	-34.94	23.04	-49.83	-5.81
EBITA, 1 Yr. Growth %	17.36	-34.91	22.9	-49.85	-5.84
EBIT, 1 Yr. Growth %	17.36	-34.91	22.9	-49.85	-5.84
Earnings From Cont. Operations, 1 Yr. Growth %	18.31	-36.01	22.44	-50.34	0.15
Net Income, 1 Yr. Growth %	18.31	-36.01	22.44	-50.34	0.15
Normalized Net Income, 1 Yr. Growth %	18.31	-36.01	22.44	-50.34	0.15
Diluted EPS Before Extra, 1 Yr. Growth %	8.69	-38.21	11.49	-84	-71.4
Net Property, Plant and Equip., 1 Yr. Growth %	-30.76	91.37	-27.39	-45.48	-70.02
Total Assets, 1 Yr. Growth %	-34.64	-38.17	-74.54	-22.03	-1.14
Tangible Book Value, 1 Yr. Growth %	-37.55	-49.16	-107.69	56.6	498
Common Equity, 1 Yr. Growth %	-37.57	-49.16	-107.69	56.6	498
Cash From Operations, 1 Yr. Growth %	27.77	-25.36	37.96	-19.32	-38.88
Capital Expenditures, 1 Yr. Growth %	168.35	-88.68	20.83	-82.76	-
Levered Free Cash Flow, 1 Yr. Growth %	98.02	-36.23	55.57	3.25	-53.65
Unlevered Free Cash Flow, 1 Yr. Growth %	98.02	-36.23	55.57	2.75	-55.38
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	56.37	-12.6	-10.53	-21.43	-31.26
EBITA, 2 Yr. CAGR %	56.1	-12.6	-10.56	-21.49	-31.28
EBIT, 2 Yr. CAGR %	56.1	-12.6	-10.56	-21.49	-31.28
Earnings From Cont. Operations, 2 Yr. CAGR %	57.71	-12.99	-11.48	-22.02	-29.48
Net Income, 2 Yr. CAGR %	57.71	-12.99	-11.48	-22.02	-29.48
Normalized Net Income, 2 Yr. CAGR %	57.71	-12.99	-11.48	-22.02	-29.48
Diluted EPS Before Extra, 2 Yr. CAGR %	18.34	-18.05	-17	-57.77	-78.61
Net Property, Plant and Equip., 2 Yr. CAGR %	-30.17	15.11	17.88	-37.08	-59.57
Total Assets, 2 Yr. CAGR %	-9.37	-36.43	-60.33	-55.45	-12.2
Tangible Book Value, 2 Yr. CAGR %	-11.05	-43.65	-80.23	-65.31	206.02
Common Equity, 2 Yr. CAGR %	-11.1	-43.66	-80.23	-65.31	206.02
Cash From Operations, 2 Yr. CAGR %	41.73	-2.34	1.47	5.5	-29.77
Capital Expenditures, 2 Yr. CAGR %	44.17	-44.88	-63.01	-54.36	-
Levered Free Cash Flow, 2 Yr. CAGR %	46.25	12.37	-0.4	26.74	-30.34
Unlevered Free Cash Flow, 2 Yr. CAGR %	46.25	12.37	-0.4	26.43	-31.82
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	31.04	16.74	-2.05	-26.22	-16.54
EBITA, 3 Yr. CAGR %	31.01	16.62	-2.08	-26.25	-16.59
EBIT, 3 Yr. CAGR %	31.01	16.62	-2.08	-26.25	-16.59
Earnings From Cont. Operations, 3 Yr. CAGR %	31.31	16.76	-2.49	-26.99	-15.24
Net Income, 3 Yr. CAGR %	31.31	16.76	-2.49	-26.99	-15.24
Normalized Net Income, 3 Yr. CAGR %	31.31	16.76	-2.49	-26.99	-15.24
Diluted EPS Before Extra, 3 Yr. CAGR %	-5.33	-4.71	-9.2	-52.06	-62.91
Net Property, Plant and Equip., 3 Yr. CAGR %	48.22	-2.28	-1.28	-8.84	-50.85
Total Assets, 3 Yr. CAGR %	69.76	-20.22	-53.14	-50.31	-41.89
Tangible Book Value, 3 Yr. CAGR %	74.63	-26.18	-70.99	-60.59	-10.38
Common Equity, 3 Yr. CAGR %	74.04	-26.21	-71	-60.59	-10.38
Cash From Operations, 3 Yr. CAGR %	23.11	14.45	9.58	-5.99	-12.05
Capital Expenditures, 3 Yr. CAGR %	-13.63	-38.26	-28.4	-71.32	-
Levered Free Cash Flow, 3 Yr. CAGR %	24.51	10.9	25.24	0.8	-8.94
Unlevered Free Cash Flow, 3 Yr. CAGR %	24.51	10.9	25.24	0.64	-10.24
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	35.76	29.33	12.49	-0.36	-14.98
EBITA, 5 Yr. CAGR %	35.6	29.22	12.46	-0.45	-15.01
EBIT, 5 Yr. CAGR %	35.6	29.22	12.46	-0.45	-15.01
Earnings From Cont. Operations, 5 Yr. CAGR %	35.63	29.14	12.15	-0.65	-14.35
Net Income, 5 Yr. CAGR %	35.63	29.14	12.15	-0.65	-14.35
Normalized Net Income, 5 Yr. CAGR %	35.63	29.14	12.15	-0.65	-14.35
Diluted EPS Before Extra, 5 Yr. CAGR %	-8.07	-2.78	-10.18	-31.18	-49.07
Net Property, Plant and Equip., 5 Yr. CAGR %	33.19	60.63	35.24	-18.06	-30.92
Total Assets, 5 Yr. CAGR %	57.02	33.65	-5.09	-36.8	-39.76
Tangible Book Value, 5 Yr. CAGR %	59.01	29.91	-26.94	-45.42	-25.56
Common Equity, 5 Yr. CAGR %	58.9	29.9	-27.09	-45.44	-25.57
Cash From Operations, 5 Yr. CAGR %	28.44	25.89	13.95	10.79	-8.29
Capital Expenditures, 5 Yr. CAGR %	134.34	13.05	-38.48	-45.29	-
Levered Free Cash Flow, 5 Yr. CAGR %	29.28	22.74	13.88	16.98	-0.95
Unlevered Free Cash Flow, 5 Yr. CAGR %	29.28	22.74	13.88	16.87	-1.8